



Tesofensine

Tesofensine is a dopamine, serotonin, and noradrenaline (triple) reuptake inhibitor originally developed to treat neurological disorders such as Parkinson's disease (PD) and Alzheimer's disease.

Although tesofensine was not efficient in PD trials, overweight participants achieved significant weight loss. Tesofensine was changed from development for these applications as it showed limited efficacy. It did show consistent weight loss especially in overweight or obese patients. Tesofensine, an inhibitor of presynaptic uptake of the neurotransmitters serotonin, noradrenaline, and dopamine, acts primarily as an appetite suppressant with simultaneous effects on fat oxidation and resting energy expenditure. Clinical trial data suggests it may potentially achieve more significant reductions in weight than that seen with currently approved weight loss agents. In Phase 2 clinical studies, weight loss over six months was more effective than other available weight loss drugs. Patients lost an average of 12.8 kg on the 1 mg dose, 11.3 kg on the 0.5 mg dose, and 6.7 kg on the 0.25 mg dose.

- Significantly affected appetite
- Reduction in expected next meal size
- Decreased desires for sweet, fatty, or salty foods
- Improvement in quality of life in Physical Function, Self Esteem, Sexual Life, Public Distress, and Work.

